Skip to content
TrialScanner

NCT04052997

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2CompletedADCTLead

Registry record

Lead sponsor
ADC Therapeutics S.A.
Conditions
Relapsed Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
Primary completion
Jan 19, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04052997 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04052997: Study to Evaluate the... | TrialScanner